Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Plus Lenvatinib as Neoadjuvant Therapy for Resectable HCC
NCT07475026Phase 3Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jun 2026
- Primary completion
- Jan 2030
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tislelizumab, lenvatinib in hepatocellular carcinoma (HCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Jun 2026; status: recruiting.
02
Drugs
tislelizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07475026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07475026.